HUYABIO International Reports Promising Phase 1 Results for HBI-3000 in Atrial Fibrillation Treatment HUYABIO International's newly developed drug HBI-3000 shows positive Phase 1 clinical results, offering hope for safer atrial fibrillation treatment with lower risks.

HUYABIO International Reports Promising Phase 1 Results for HBI-3000 in Atrial Fibrillation Treatment #United_States #San_Diego #Atrial_Fibrillation #HBI-3000 #sulcardine